S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard

Inhibrx (INBX) Stock Price, News & Analysis

$38.33
+0.05 (+0.13%)
(As of 02/22/2024 ET)
Today's Range
$38.15
$38.80
50-Day Range
$27.89
$38.75
52-Week Range
$14.31
$39.50
Volume
229,418 shs
Average Volume
498,837 shs
Market Capitalization
$1.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.50

Inhibrx MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
4.8% Downside
$36.50 Price Target
Short Interest
Healthy
6.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.21
Upright™ Environmental Score
News Sentiment
1.76mentions of Inhibrx in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.45) to ($4.34) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.68 out of 5 stars

Medical Sector

236th out of 937 stocks

Biological Products, Except Diagnostic Industry

35th out of 158 stocks


INBX stock logo

About Inhibrx Stock (NASDAQ:INBX)

Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.

INBX Stock Price History

INBX Stock News Headlines

Elon Musk's "Project Dojo" is a Game-Changer
Morgan Stanley predicts that Musk's latest act will boost Tesla's shares by 80% in the next 12 months. But if you want to profit from this development, you'll buy the firm that could see its sales explode by 829% as "Project Dojo" sweeps the nation.
Inhibrx just downgraded at LifeSci Capital, here's why
Elon Musk's "Project Dojo" is a Game-Changer
Morgan Stanley predicts that Musk's latest act will boost Tesla's shares by 80% in the next 12 months. But if you want to profit from this development, you'll buy the firm that could see its sales explode by 829% as "Project Dojo" sweeps the nation.
Inhibrx Inc Ordinary Shares INBX
Inhibrx Inc Ordinary Shares
Inhibrx posts Q3 results
JMP Securities Reaffirms Their Buy Rating on Inhibrx (INBX)
See More Headlines
Receive INBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
2/23/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:INBX
Fax
N/A
Employees
132
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.50
High Stock Price Target
$46.00
Low Stock Price Target
$27.00
Potential Upside/Downside
-4.8%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-145,230,000.00
Net Margins
-42,880.00%
Pretax Margin
-42,878.64%

Debt

Sales & Book Value

Annual Sales
$2.19 million
Book Value
$1.33 per share

Miscellaneous

Free Float
36,792,000
Market Cap
$1.81 billion
Optionable
Optionable
Beta
3.03
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives















INBX Stock Analysis - Frequently Asked Questions

Should I buy or sell Inhibrx stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INBX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INBX, but not buy additional shares or sell existing shares.
View INBX analyst ratings
or view top-rated stocks.

What is Inhibrx's stock price target for 2024?

3 brokers have issued 12-month target prices for Inhibrx's shares. Their INBX share price targets range from $27.00 to $46.00. On average, they expect the company's share price to reach $36.50 in the next year. This suggests that the stock has a possible downside of 4.8%.
View analysts price targets for INBX
or view top-rated stocks among Wall Street analysts.

How have INBX shares performed in 2024?

Inhibrx's stock was trading at $38.00 at the start of the year. Since then, INBX shares have increased by 0.9% and is now trading at $38.33.
View the best growth stocks for 2024 here
.

Are investors shorting Inhibrx?

Inhibrx saw a decrease in short interest in January. As of January 31st, there was short interest totaling 2,400,000 shares, a decrease of 41.3% from the January 15th total of 4,090,000 shares. Based on an average trading volume of 715,000 shares, the short-interest ratio is presently 3.4 days. Approximately 6.7% of the company's shares are short sold.
View Inhibrx's Short Interest
.

When is Inhibrx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our INBX earnings forecast
.

How were Inhibrx's earnings last quarter?

Inhibrx, Inc. (NASDAQ:INBX) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.54) earnings per share for the quarter, topping analysts' consensus estimates of ($0.60) by $0.06. The business earned $2.53 million during the quarter, compared to analyst estimates of $1 million. Inhibrx had a negative net margin of 42,880.00% and a negative trailing twelve-month return on equity of 424.05%.

What other stocks do shareholders of Inhibrx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), Activision Blizzard (ATVI), Daqo New Energy (DQ), Fastly (FSLY), Innovative Industrial Properties (IIPR), Lovesac (LOVE) and Micron Technology (MU).

When did Inhibrx IPO?

(INBX) raised $102 million in an initial public offering on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are Inhibrx's major shareholders?

Inhibrx's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.96%), Vestal Point Capital LP (3.24%), Capital Research Global Investors (1.51%), PFM Health Sciences LP (1.14%), Russell Investments Group Ltd. (0.92%) and Northern Trust Corp (0.66%). Insiders that own company stock include Brendan P Eckelman, Global Investors Lp Viking, Jon Faiz Kayyem and Mark Lappe.
View institutional ownership trends
.

How do I buy shares of Inhibrx?

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INBX) was last updated on 2/23/2024 by MarketBeat.com Staff